View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. DPT Laboratories
18 March 2013

DPT Laboratories Receives Close-Out Letter from US FDA

DPT Laboratories received notification from the US Food and Drug Administration (FDA) on 19 February 2013 that signalled the completion of the its evaluation of DPT’s corrective actions taken at its Lakewood, NJ, facility in response to the warning letter received on 27 August 2012.

In addition, this letter communicated that in the view of the FDA, the Lakewood site is compliant with FDA regulations.

DPT worked diligently to ensure all violations noted in the warning letter were adequately addressed and continues to invest significant resources into ensuring that its compliance is world class.

The commitment and effort of the team resulted in this issue being closed out in approximately 4.5 months.

"We are pleased to have this issue behind us and appreciate the confidence our new and existing customers demonstrated in us during this time," said Eugene Ciolfi, DPT vice-president and general manager. "I am excited and optimistic about the opportunities ahead of us in 2013."

Pharmaceutical drug product development can be an expensive and time-consuming process. Many challenges are faced by pharmaceutical development companies including developing a scaleable, marketable formulation,...
With the increased globalisation and complexity of the pharmaceutical supply chain, managing the sourcing of materials has become extremely challenging. Reducing time and costs are...
This paper describes the approach and benefits of using DPT Labs' QbD Scale Up service and follows the third paper in our Thought Leadership Series,...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology